Farxiga, Forxiga(dapagliflozin)
Dapagliflozin, Ebymect, Edistride, Farxiga, Forxiga, Qtern, Qternmet, Qtrilmet, Xigduo (dapagliflozin) is a small molecule pharmaceutical. Dapagliflozin was first approved as Forxiga on 2012-11-11. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat chronic renal insufficiency, diabetes mellitus, glucose metabolism disorders, heart failure, and metabolic diseases amongst others.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Farxiga (discontinued: Dapagliflozin)
CombinationsQtern, Xigduo (discontinued: Qternmet)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dapagliflozin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| FARXIGA | AstraZeneca | N-202293 RX | 2014-01-08 | 2 products, RLD, RS |
Dapagliflozin
+
Saxagliptin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| QTERN | AstraZeneca | N-209091 RX | 2017-02-27 | 2 products, RLD, RS |
Dapagliflozin
+
Metformin hydrochloride
+
Saxagliptin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| QTERNMET XR | AstraZeneca | N-210874 DISCN | 2019-05-02 | 4 products, RLD |
Hide discontinued
Dapagliflozin
+
Metformin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| XIGDUO XR | AstraZeneca | N-205649 RX | 2014-10-29 | 5 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| dapagliflozin | NDA authorized generic | 2024-10-24 |
| dapagliflozin and metformin hydrochloride | NDA authorized generic | 2024-06-12 |
| farxiga | New Drug Application | 2024-10-24 |
| qtern | New Drug Application | 2024-11-13 |
| xigduo | New Drug Application | 2024-12-20 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
DAPAGLIFLOZIN, FARXIGA, ASTRAZENECA AB | |||
| 2024-04-30 | I-857 | ||
| 2023-05-05 | I-834 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Dapagliflozin, Farxiga, Astrazeneca Ab | |||
| 10973836 | 2040-03-09 | U-3127 | |
| 8685934 | 2030-05-26 | U-1522 | |
| 8721615 | 2030-01-18 | DP | |
| 7919598 | 2029-12-16 | DP | |
| 7851502 | 2028-08-19 | DP | |
| 8221786 | 2028-03-21 | DP | |
| 8361972 | 2028-03-21 | U-493, U-1976, U-1977, U-2139 | |
| 8716251 | 2028-03-21 | DP | |
| 8501698 | 2027-06-20 | DP | U-493, U-1976, U-1977 |
| 8329648 | 2026-08-18 | U-2139, U-2212, U-2213 | |
| 8906851 | 2026-08-18 | U-2139 | |
| 6515117 | 2025-10-04 | DS, DP | U-493, U-2139 |
| 7456254 | 2025-06-30 | DP | U-2139 |
| 8431685 | 2025-04-13 | DP | U-2139 |
| 8461105 | 2025-04-13 | DP | U-2139 |
| 9238076 | 2024-04-15 | DP | U-2139 |
| Dapagliflozin / Metformin Hydrochloride, Xigduo Xr, Astrazeneca Ab | |||
| 9616028 | 2030-11-12 | DP | |
| Dapagliflozin / Metformin Hydrochloride / Saxagliptin Hydrochloride, Qternmet Xr, Astrazeneca Ab | |||
| 8628799 | 2025-07-13 | DP | |
| RE44186 | 2023-07-31 | DS, DP | U-493 |
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BD: Combinations of oral blood glucose lowering drugs
— A10BD15: Metformin and dapagliflozin
— A10BD21: Saxagliptin and dapagliflozin
— A10BD25: Metformin, saxagliptin and dapagliflozin
— A10BK: Sodium-glucose co-transporter 2 (sglt2) inhibitors
— A10BK01: Dapagliflozin
HCPCS
No data
Clinical
Clinical Trials
611 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 30 | 17 | 75 | 96 | 53 | 266 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 9 | 14 | 71 | 78 | 39 | 206 |
| Heart failure | D006333 | HP_0001635 | I50 | 4 | 14 | 20 | 28 | 29 | 91 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 2 | 17 | 13 | 14 | 15 | 57 |
| Chronic renal insufficiency | D051436 | — | N18 | 2 | 15 | 10 | 10 | 11 | 45 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 6 | 6 | 9 | 9 | 4 | 32 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 3 | 8 | 5 | 6 | 20 |
| Infarction | D007238 | EFO_0009463 | — | — | 2 | 8 | 5 | 6 | 19 |
| Hypertension | D006973 | EFO_0000537 | I10 | 2 | 3 | 7 | 3 | 3 | 17 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | 2 | 3 | 7 | 1 | 14 |
Show 100 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | 4 | — | — | 4 |
| Weight loss | D015431 | HP_0001824 | — | — | 4 | 2 | — | — | 4 |
| Sleep apnea syndromes | D012891 | HP_0010535 | G47.3 | — | 1 | 1 | — | 1 | 3 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | 2 | 3 | — | — | 3 |
| Left ventricular dysfunction | D018487 | — | — | — | 1 | 1 | — | 1 | 3 |
| Retinal diseases | D012164 | HP_0000479 | H35.9 | — | — | 1 | — | 2 | 3 |
| Catheter ablation | D017115 | — | — | 1 | 1 | 1 | — | — | 2 |
| Unstable angina | D000789 | EFO_1000985 | I20.0 | — | — | 1 | — | 1 | 2 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 2 | 1 | — | — | 2 |
| Sepsis | D018805 | HP_0100806 | A41.9 | — | — | 1 | — | 1 | 2 |
Show 37 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 3 | — | — | 2 | 5 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 1 | 1 | — | — | 1 | 3 |
| Cystinuria | D003555 | — | E72.01 | — | 2 | — | — | — | 2 |
| Triple negative breast neoplasms | D064726 | — | — | 1 | 1 | — | — | — | 2 |
| Amyloidosis | D000686 | EFO_1001875 | E85 | — | 1 | — | — | 1 | 2 |
| Respiratory aspiration | D053120 | EFO_1001839 | — | — | 1 | — | — | — | 1 |
| Diastolic heart failure | D054144 | EFO_1000899 | I50.30 | — | 1 | — | — | — | 1 |
| Aging | D000375 | GO_0007568 | R41.81 | 1 | 1 | — | — | — | 1 |
| Heart disease risk factors | D000082742 | — | — | — | 1 | — | — | — | 1 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | 1 | — | — | — | 1 |
Show 17 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 23 | — | — | — | 1 | 24 |
| Diabetic ketoacidosis | D016883 | EFO_1000897 | — | 1 | — | — | — | 2 | 3 |
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | 1 | 2 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 1 | — | — | — | — | 1 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
| Reperfusion injury | D015427 | — | — | 1 | — | — | — | — | 1 |
| Vascular ring | D000073872 | — | Q25.45 | 1 | — | — | — | — | 1 |
| Hyperinsulinism | D006946 | HP_0000842 | E16.1 | 1 | — | — | — | — | 1 |
Show 3 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 3 | 3 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | — | — | 3 | 3 |
| Communicable diseases | D003141 | — | — | — | — | — | — | 1 | 1 |
| Body weight changes | D001836 | — | — | — | — | — | — | 1 | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | — | — | — | 1 | 1 |
| Chemical and drug induced liver injury | D056486 | EFO_0004228 | — | — | — | — | — | 1 | 1 |
| Mitochondrial diseases | D028361 | EFO_0000591 | — | — | — | — | — | 1 | 1 |
| Systolic murmurs | D054160 | — | R01.1 | — | — | — | — | 1 | 1 |
| Tricuspid valve insufficiency | D014262 | HP_0005180 | — | — | — | — | — | 1 | 1 |
| Exercise test | D005080 | EFO_0004328 | — | — | — | — | — | 1 | 1 |
Show 6 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dapagliflozin |
| INN | dapagliflozin |
| Description | Dapagliflozin is a C-glycosyl comprising beta-D-glucose in which the anomeric hydroxy group is replaced by a 4-chloro-3-(4-ethoxybenzyl)phenyl group. Used (in the formo f its propanediol monohydrate) to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes. It has a role as a hypoglycemic agent and a sodium-glucose transport protein subtype 2 inhibitor. It is a C-glycosyl compound, an organochlorine compound and an aromatic ether. |
| Classification | Small molecule |
| Drug class | phlorozin derivatives, phenolic glycosides |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 461432-26-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL429910 |
| ChEBI ID | 85078 |
| PubChem CID | 9887712 |
| DrugBank | DB06292 |
| UNII ID | 1ULL0QJ8UC (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Qtern – AstraZeneca
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Farxiga – AstraZeneca
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Forxiga – Bristol Myers Squibb
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Dapagliflozin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 13,198 documents
View more details
Safety
Black-box Warning
Black-box warning for: Dapagliflozin and metformin hydrochloride, Xigduo
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
31,835 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use